The Justice Department claims Ambu manufactured medical products in China and Malaysia and sold them to U.S. government agencies in violation of the Trade Agreements Act, which requires that products sold to government agencies must only come from countries that have a trade agreement with the U.S.
The settlement resolves allegations that Ambu submitted false claims to the Defense Logistics Agency and Department of Veterans’ Affairs about the manufacturing of the devices and payments related to the sale of the medical supplies.
“Congress passed the Trade Agreements Act as an important part of the U.S. economic, diplomatic, and defense strategy,” said U.S. Attorney William McSwain. “Contractors must follow the law and manufacture their products in TAA-compliant countries, whether they like it or not. By investigating the allegations and reaching a settlement in this case, we have put all companies doing business with the U.S. government on notice that the TAA is an important law that must be respected.”
More articles on supply chain:
5 top supply chain stories in July
FedEx drops ground-delivery contract with Amazon
How US-China trade tensions are affecting the medical device industry
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
